Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : InvestRight Club Challenge -- Ignore unavailable to you. Want to Upgrade?

To: Stroke who wrote (1987)	5/6/1999 11:18:00 PM
From: whyretire	Respond to of 2662

SMPX news biz.yahoo.com excerpt from press release: Symphonix Devices, Inc. Reports First Quarter Financial Results SAN JOSE, Calif., May 6 /PRNewswire In the United States, Symphonix reported that it expects to complete follow-up of its pivotal trial of the Vibrant P soundridge during the second quarter of 1999. Harry S. Robbins, Symphonix Chief Executive Officer, stated, ''We have now submitted to the FDA, under the modular PMA process, a total of seven modules, five of which have already been reviewed and accepted by the FDA.'' Symphonix also announced that it had received FDA approval of an IDE supplement permitting the evaluation of the Vibrant D soundbridge, the Company's latest generation product incorporating 100% digital technology . Harry S. Robbins stated, ''After fitting the device to many of our existing patients, the initial results from the Vibrant D soundbridge have been encouraging and we anticipate being able to submit data for the Vibrant D and Vibrant P soundbridges simultaneously to the FDA in a PMA submission.''